arrow
L

Laura Sepp-Lorenzino

intellia therapeutics, cambridge, massachusetts, usa
H指数:44
被引数:8,295

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

CRISPR-Cas9 In Vivo Gene Editing of KLKB1 for Hereditary Angioedema

KLKB1基因编辑在遗传性血管性水肿中的体内CRISPR-Cas9

2024-02-0145
PRE
Evaluation of RNAi therapeutics VIR-2218 and ALN-HBV for chronic hepatitis B: Results from randomized clinical trials
2023-10-0135
OA
From bench to bedside: Improving the clinical safety of GalNAc-siRNA conjugates using seed-pairing destabilization
2022-06-2343
OAAI
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis

转甲状腺素蛋白淀粉样变性的体内基因编辑CRISPR-Cas9

2021-08-05934
OAAI
Centyrin ligands for extrahepatic delivery of siRNA
2021-06-0131
OAAI
Safety evaluation of 2-deoxy-2-fluoro nucleotides in GalNAc-siRNA conjugates
2019-03-0161
OAAI
Titrating haemophilia B phenotypes using siRNA strategy: evidence that antithrombotic activity is separated from bleeding liability
2017-11-228
PREAI
Proof-of-concept Studies for siRNA-mediated Gene Silencing for Coagulation Factors in Rat and Rabbit
2015-01-0128
OAAI
An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo
2014-10-2758
OAAI